About: Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review
Creator	Dutta, Shanta Bhatta, Mihir Biswas, Subrata Chakraborty, Debjit Deb, Alok Debnath, Falguni Ganguly, Suman Kumar Saha, Malay
Source	Medline; PMC
abstract	Despite high morbidity and mortality of ongoing coronavirus disease 2019 (COVID-19) pandemic, no specific therapy has been established till date. Though in vitro studies identified various molecules as possible therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), these findings call for substantiation by human studies. We conducted this review aiming at reporting evidences on therapies used so far globally for management of COVID-19 in clinical settings. We searched electronic databases as PubMed, Google Scholar, EMBASE and extracted 612 possible studies as on May 31, 2020. We included original studies of any epidemiological design done on human COVID-19 patients and measured clinical outcomes. Finally, following removal of duplicates and studies meeting exclusion criteria, we derived 22 studies, of which eight were clinical trials, seven were case reports and case series, and seven were observational studies. The most reported therapies were hydroxychloroquine (HCQ) (eight studies) and lopinavir/ritonavir (four studies). We conclude from the evidence generated so far that interferon combined with antivirals, remdesivir, umifenovir and favipiravir were mostly associated with better clinical outcomes. The therapeutic effect of HCQ was established initially by two clinical trials; one of them showing a reinforcing effect by azithromycin but subsequent studies did not elicit any effectiveness rather increased rate of adverse events was reported. Lopinavir/ritonavir was found beneficial when administered with interferon and ribavirin, but one clinical trial on its sole use proved contrary. As many clinical trials are in process, we expect to get concrete evidences on repurposing of existing drugs based on less biased, high powered studies.
has issue date	2020-07-22(xsd:dateTime)
bibo:doi	10.14740/jocmr4241
bibo:pmid	32849934
has license	cc-by-nc
sha1sum (hex)	121c1f530e324312726c9e1f7ab842e107f148a0
schema:url	https://doi.org/10.14740/jocmr4241
resource representing a document's title	Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review
has PubMed Central identifier	PMC7430870
has PubMed identifier	32849934
schema:publication	J Clin Med Res
resource representing a document's body	covid:121c1f530e324312726c9e1f7ab842e107f148a0#body_text
is schema:about of	named entity 'reinforcing' named entity 'case series' named entity 'human' named entity 'drugs' named entity 'clinical trial' named entity 'umifenovir' named entity 'interferon' named entity 'aiming' named entity 'extracted' named entity 'therapeutic' named entity 'BIASED' named entity 'STUDIES' named entity 'GENERATED' covid:arg/121c1f530e324312726c9e1f7ab842e107f148a0 named entity 'substantiation' named entity 'high' named entity 'favipiravir' named entity 'clinical trials' named entity 'ongoing' named entity 'Google Scholar' named entity 'remdesivir' named entity 'transmission rate' named entity 'significant difference' named entity 'RNA-dependent RNA polymerase' named entity 'antivirals' named entity 'tumor necrosis factor-α' named entity 'active form' named entity 'radiography' named entity 'Umifenovir' named entity 'placebo' named entity 'statistical power' named entity 'clinical trial' named entity 'metabolize' named entity 'virus' named entity 'CFR' named entity 'remdesivir' named entity 'dyspnea' named entity 'favipiravir' named entity 'RdRP' named entity 'therapeutic agents' named entity 'Google Scholar' named entity 'France' named entity 'viral load' named entity 'RNA viruses' named entity 'open-label trial' named entity 'phosphorylated' named entity 'purine nucleosides' named entity 'treatment group' named entity 'cohort analysis' named entity 'methylprednisolone' named entity 'COVID' named entity 'proofreading' named entity 'remdesivir' named entity 'control group' named entity 'APACHE II' named entity 'randomized control trial' named entity 'nasopharyngeal swab' named entity 'antivirals' named entity 'cardiac arrest' named entity 'interferon-stimulated genes' named entity 'antivirals' named entity 'prophylactic' named entity 'secretion' named entity 'ritonavir' named entity 'interleukins' named entity 'control arm' named entity 'IFN' named entity '95% CI' named entity 'interferon' named entity 'epidemic' named entity 'favipiravir' named entity 'C-reactive protein' named entity 'remdesivir' named entity 'pneumonia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software